Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, and its news flow reflects this GI specialization. Company updates frequently center on VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) that Phathom markets in the United States for adult patients with Erosive GERD, Non-Erosive GERD, and Helicobacter pylori infection in combination regimens.
Investors and healthcare observers following PHAT news can expect regular announcements on commercial performance, including prescription milestones and revenue updates tied to VOQUEZNA tablets, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Phathom’s press releases have highlighted metrics such as total VOQUEZNA prescriptions dispensed in the United States and quarterly financial results, often accompanied by commentary on commercialization strategy and expense trends.
Another major category of Phathom news involves clinical and scientific developments. The company reports progress in trials like the Phase 3 pHalcon-NERD-301 study in Non-Erosive GERD and the Phase 2 pHalcon-EoE-201 study evaluating VOQUEZNA in eosinophilic esophagitis. Publications in peer-reviewed journals and presentations at gastroenterology conferences, such as the American College of Gastroenterology Annual Scientific Meeting, are common topics in its releases.
Phathom also issues news on capital markets activity, including proposed and priced underwritten public offerings of common stock and pre-funded warrants, as well as corporate updates such as leadership appointments and participation in investor conferences. Together, these news items provide a view into the company’s GI-focused strategy, clinical pipeline, commercial trajectory, and financing plans. For users tracking PHAT, the news page offers a consolidated stream of these developments over time.
Phathom Pharmaceuticals (NASDAQ: PHAT) appointed Sanjeev Narula as Chief Financial and Business Officer on October 6, 2025. Mr. Narula is described as experienced in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, mergers & acquisitions, and operations.
Management says the hire strengthens leadership as Phathom executes its growth strategy, targets profitability, and commercializes VOQUEZNA, which the company says is gaining traction.
Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal treatments, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 9:10 am EDT and the H.C. Wainwright Global Investment Conference on September 8 at 1:00 pm EDT.
Phathom's management team will conduct one-on-one meetings during both conferences. The company currently markets VOQUEZNA®, a first-in-class potassium-competitive acid blocker (PCAB) for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment.
Phathom Pharmaceuticals (NASDAQ: PHAT) has issued a clarification regarding a Schedule 13D filing by Frazier Life Sciences. The company emphasized that the upcoming filing includes only administrative changes to the reporting approach and does not represent any reduction in Frazier's ownership position in Phathom.
While the updated filing may show different breakouts of holdings between funds and persons, and changes in warrant treatment may affect certain percentage calculations, these modifications are purely administrative in nature. The company confirms that no actual sale of shares has occurred.
Phathom Pharmaceuticals (NASDAQ:PHAT) reported strong Q2 2025 financial results, with net revenues of $39.5 million, up significantly from $7.3 million in Q2 2024. The company's VOQUEZNA® products reached over 580,000 filled prescriptions, showing 49% growth since the last earnings report. Commercial coverage remains robust with access to over 120 million lives.
The company provided full-year 2025 revenue guidance of $165-175 million and expects to achieve profitability in 2026. Q2 net loss was $75.8 million, improved from $91.4 million in Q2 2024. Cash position stands at $149.6 million as of June 30, 2025. The FDA has updated VOQUEZNA's exclusivity through May 2032, with generic entry unlikely before 2033.
Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, will host a webcast on August 7, 2025, at 8:00 am EDT to discuss Q2 2025 financial results and provide a business update.
The company markets VOQUEZNA® (vonoprazan) tablets in the US for heartburn relief and GERD treatment, along with VOQUEZNA® TRIPLE PAK® and VOQUEZNA® DUAL PAK® for H. pylori infection treatment. The webcast will be accessible through Phathom's investor relations website, with a recording available for 90 days following the event.
Phathom Pharmaceuticals (NASDAQ: PHAT) announced the approval of inducement awards for their newly appointed Chief Legal Officer and Corporate Secretary, Anne Marie Cook. The compensation package includes a non-qualified stock option to purchase 210,000 shares of Phathom common stock, with 25% vesting on June 23, 2026, and the remainder vesting in 36 monthly installments. Additionally, Cook received 50,400 performance stock units with potential earnings up to 200% of target, tied to company financial objectives through December 31, 2027.
The awards are granted under the company's 2025 Employment Inducement Incentive Award Plan and comply with Nasdaq Listing Rule 5635(c)(4). Phathom specializes in developing treatments for gastrointestinal diseases and markets VOQUEZNA® in the United States.
Phathom Pharmaceuticals (NASDAQ: PHAT), a biopharmaceutical company specializing in gastrointestinal disease treatments, has announced its participation in three upcoming investor conferences:
1. H.C. Wainwright BioConnect Investor Conference on May 20, 2025, at 4:00 p.m. ET in New York
2. Jefferies Global Healthcare Conference on June 5, 2025, at 9:55 a.m. ET in New York
3. Goldman Sachs Global Healthcare Conference on June 11, 2025, at 10:40 a.m. ET in Miami Beach
The company will conduct one-on-one meetings at all events. Live webcasts and 90-day archived recordings will be available on Phathom's investor relations website.